Completed PHASE3 INTERVENTIONAL NCT00040495

Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Peptic Ulcer Hemorrhage

Interventions Pantoprazole

Updated 6 times since 2017 Last updated: Feb 7, 2013 Started: Apr 30, 2001 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Peptic Ulcer Hemorrhage, this trial is completed. The trial is conducted by Wyeth is now a wholly owned subsidiary of Pfizer and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.